1. Home
  2. Directory
  3. Wisconsin
  4. Madison
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1154612554

DR. STEPHEN J HALLIDAY M.D., MSCI
Prescription History 1154612554
Internal Medicine - Pulmonary Disease in Madison, WI

NPI Status: Active since April 20, 2011

Contact Information

600 HIGHLAND AVE
MADISON, WI
ZIP 53792
Phone: (608) 263-6400

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEPHEN J HALLIDAY M.D., MSCI, an active Pulmonary Disease specialist practicing in Madison, WI. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 229 documented patient claims. Among these therapy options, the most frequently utilized medication is Mycophenolate Mofetil, which accounts for 109 claims alone.

Medication Index

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 460
WI State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.3
Peer Average Days Supply349
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $432.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.82

State Avg Cost Per Claim

$12.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 109
30-Day Fills 148.9
Days Supply 4,287
WI State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills47.0
Peer Average Days Supply1,391
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 319.2% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,268.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.03

State Avg Cost Per Claim

$138.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,230
WI State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply822
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 51.9% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $518,842.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,654.70

State Avg Cost Per Claim

$12,285.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
WI State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply506
Conservative Utilization

This provider writes prescriptions for this formulation 31.3% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,320.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,301.82

State Avg Cost Per Claim

$6,435.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 45.5
Days Supply 1,175
WI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,056
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $224.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.23

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 476
WI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply449
Conservative Utilization

This provider writes prescriptions for this formulation 26.1% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.45

State Avg Cost Per Claim

$6.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEPHEN J HALLIDAY M.D., MSCI provides transparency into local medical care patterns within Madison, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.